Screener
Allogene Therapeutics ALLO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Operating lease right-of-use asset | 38,819 | 39,888 |
| Property and equipment, net | 70,023 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 |
| Total assets | $395,958 | $415,905 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's restricted cash?
- Allogene Therapeutics (ALLO) reported restricted cash of $10.29M in Q1 2026.
- How has Allogene Therapeutics's restricted cash changed year-over-year?
- Allogene Therapeutics's restricted cash decreased by 0.0% year-over-year, from $10.29M to $10.29M.
- What is the long-term trend for Allogene Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Allogene Therapeutics's restricted cash has grown at a 1.7% compound annual growth rate (CAGR), from $9.45M to $10.29M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Allogene Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude